WallStSmart
SRRK

Scholar Rock Holding Corp

NASDAQ: SRRK · HEALTHCARE · BIOTECHNOLOGY

$44.18
-1.14% today

Updated 2026-06-12

Market cap
$5.29B
P/E ratio
P/S ratio
13.14x
EPS (TTM)
$-3.45
Dividend yield
52W range
$27 – $52
Volume
1.4M

Scholar Rock Holding Corp (SRRK) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2016201720182019202020212022202320242025
Revenue$379000.00$0.00$0.00$20.49M$15.40M$18.82M$33.19M$0.00$0.00$0.00
Revenue growth (YoY)-100.0%-24.8%+22.2%+76.4%-100.0%
Cost of revenue$12.48M$669000.00$36.31M$54.22M$74.06M$108.47M$9.88M$2.84M$1.94M$1.66M
Gross profit$-12.10M$-669000.00$-36.31M$20.49M$15.40M$-89.65M$33.19M$-2.84M$-1.94M$-1.66M
Gross margin-3192.1%100.0%100.0%-476.5%100.0%
R&D$12.48M$19.94M$36.31M$54.22M$74.06M$108.47M$124.44M$119.06M$182.61M$208.44M
SG&A$4.11M$5.08M$14.38M$20.82M$28.22M$40.27M$43.12M$49.40M$67.50M$176.21M
Operating income$-16.21M$-25.03M$-50.69M$-54.54M$-86.88M$-129.92M$-134.37M$-171.29M$-252.05M$-384.64M
Operating margin-4277.0%-266.2%-564.0%-690.5%-404.8%
EBITDA$-15.63M$-24.36M$-49.88M$-53.24M$-85.39M$-127.29M$-131.38M$-162.94M$-237.52M$-369.39M
EBITDA margin-4125.3%-259.8%-554.4%-676.5%-395.8%
EBIT$-16.21M$-25.03M$-50.69M$-54.54M$-86.88M$-129.92M$-134.37M$-165.79M$-239.46M$-371.05M
Interest expense$19000.00$0.00$0.00$0.00$0.00$1.88M$2.85M$6.84M$6.89M
Income tax$19000.00$-44000.00$1.37M$-1.30M$-1.49M$2.39M$-2.85M$2.68M
Effective tax rate-0.1%0.2%-2.8%2.6%1.7%-1.8%2.1%-1.6%0.0%0.0%
Net income$-16.21M$-25.00M$-49.33M$-49.70M$-84.99M$-131.80M$-131.65M$-165.79M$-246.29M$-377.94M
Net income growth (YoY)-54.2%-97.3%-0.8%-71.0%-55.1%+0.1%-25.9%-48.6%-53.5%
Profit margin-4276.3%-242.5%-551.8%-700.5%-396.6%

Frequently asked questions

How much free cash flow does SRRK generate?

SRRK produced $-300.64M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SRRK's balance sheet healthy?

SRRK holds $323.53M in cash and equivalents against $99.71M in long-term debt, on $245.49M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.